154 related articles for article (PubMed ID: 35861435)
41. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
[TBL] [Abstract][Full Text] [Related]
42. Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.
Sesé M; Somoza R; Maestu I; Ureste MM; Sanchez A; Cordoba JF; Sansano I; Venturas G; Ramón Y Cajal S; Hernández-Losa J
Oncol Ther; 2019 Dec; 7(2):131-139. PubMed ID: 32699985
[TBL] [Abstract][Full Text] [Related]
43. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.
van Dessel LF; Vitale SR; Helmijr JCA; Wilting SM; van der Vlugt-Daane M; Oomen-de Hoop E; Sleijfer S; Martens JWM; Jansen MPHM; Lolkema MP
Mol Oncol; 2019 Feb; 13(2):392-402. PubMed ID: 30516338
[TBL] [Abstract][Full Text] [Related]
44. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
45. Performance comparison of commercial kits for isolating and detecting circulating tumor DNA.
Wang M; Huang X; Li X; Guo Q; Xu W; Zhao M; Wang X; Wang L; Lou J
Scand J Clin Lab Invest; 2021 Jul; 81(4):276-281. PubMed ID: 33999736
[TBL] [Abstract][Full Text] [Related]
46. Oncological Assessment of Stent Placement for Obstructive Colorectal Cancer from Circulating Cell-Free DNA and Circulating Tumor DNA Dynamics.
Takahashi G; Yamada T; Iwai T; Takeda K; Koizumi M; Shinji S; Uchida E
Ann Surg Oncol; 2018 Mar; 25(3):737-744. PubMed ID: 29235008
[TBL] [Abstract][Full Text] [Related]
47. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
48. Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.
Ahlborn LB; Madsen M; Jonson L; Nielsen FC; Lassen U; Yde CW; Mau-Sorensen M
Clin Lab; 2017 Oct; 63(10):1755-1759. PubMed ID: 29035458
[TBL] [Abstract][Full Text] [Related]
49. A novel urine cell-free DNA preservation solution and its application in kidney transplantation.
Zhou Q; Liu F; Guo L; Chen R; Yuan X; Li C; Shu L; Liu H; Zhou Y; Wu Y; Shi H; Zhao H; Jiang T
Nephrology (Carlton); 2021 Aug; 26(8):684-691. PubMed ID: 33866646
[TBL] [Abstract][Full Text] [Related]
50. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
[TBL] [Abstract][Full Text] [Related]
51. Effect of preexamination conditions in a centralized-testing model of non-invasive prenatal screening.
Fibke C; Giroux S; Caron A; Starks E; Parker JDK; Swanson L; Jouan L; Langlois S; Rouleau G; Rousseau F; Karsan A
Clin Chem Lab Med; 2022 Jan; 60(2):183-190. PubMed ID: 34761647
[TBL] [Abstract][Full Text] [Related]
52. Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics.
Wang F; Li X; Li M; Liu W; Lu L; Li Y; Chen X; Yang S; Liu T; Cheng W; Weng L; Wang H; Lu D; Yao Q; Wang Y; Wu J; Wittkop T; Faham M; Zhou H; Hu H; Jin H; Hu Z; Ma D; Cheng X
Clin Chem Lab Med; 2024 Jan; 62(1):168-177. PubMed ID: 37678194
[TBL] [Abstract][Full Text] [Related]
53. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
[TBL] [Abstract][Full Text] [Related]
54. Hemolysis and Fetal Fraction in Cell-Free DNA Blood Collection Tubes for Noninvasive Prenatal Testing.
Stokowski R; White K; Hacker C; Doshi J; Schmid M
Mol Diagn Ther; 2020 Apr; 24(2):185-190. PubMed ID: 32056107
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
56. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
57. Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.
Ottestad AL; Dai HY; Halvorsen TO; Emdal EF; Wahl SGF; Grønberg BH
Cancer Treat Res Commun; 2021; 29():100471. PubMed ID: 34607221
[TBL] [Abstract][Full Text] [Related]
58. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
59. A nano-magnetic size selective cfDNA extraction platform for liquid biopsy with enhanced precision.
Liu Y; Cheng L; Wang G; Lv J; He Y; Shao PL; Hu R; Xiao H; Tang J; Niu D; Yang J; Tang Z; Xu Z; Liu Y; Li Y; Song K; Wu B; Zhang B
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123236. PubMed ID: 35472714
[TBL] [Abstract][Full Text] [Related]
60. Plasma Sequencing for Patients with GIST-Limitations and Opportunities in an Academic Setting.
Falkenhorst J; Grunewald S; Krzeciesa D; Herold T; Ketzer J; Christoff M; Hamacher R; Kostbade K; Treckmann J; Köster J; Farzaliyev F; Fletcher BS; Dieckmann N; Kaths M; Mühlenberg T; Schildhaus HU; Bauer S
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
